~~<i id='F6B300DD59'><strike id='F6B300DD59'><tt id='F6B300DD59'><pre id='F6B300DD59'></pre></tt></strike></i>~~

Home» knowledge» fashion

fashion

author：hotspot 2025-10-01 22:38:08 Page View：8624

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Insitro, AI biotech unicorn, brings cash, new research to JPM 2024
Next article： Psychedelics group wrestles with new pharma identity

explore

Medicare proposal to cover medical devices draws a mixed reaction

AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

Videos point to link between seizures and unexplained toddler deaths

KatieCzajkowski-Fellholdingaphotoofherhusband,JustinFell,withtheirtwinsonsCameron(left)andHayden.And

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

3 trends to watch in health tech's hiring outlook for 2024

ChristineKao/STATHealthtechhopefulsmightoncehavebeenusedtoawealthofjoboptions,especiallyinthepandemi